CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 80 enrolled
Drug / intervention
Barley beta-glucan(3.0g) +1 moredietary
Likely dose
Barley beta-glucan(3.0g)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01402128
NCT01402128Phase 3Completed
CompareCT.gov

The Effect of Barley Beta-glucan on Serum Lipids and Body Weight

Chonbuk National University Hospital·interventional·Posted Jul 26, 2011·Updated Dec 25, 2012

In Brief

A Phase 3 clinical trial evaluating Barley beta-glucan(3.0g) and Placebo for Overweight; Hyperlipidemia. Completed, enrolled 80 participants across 1 site.

Detailed Summary

Barley, like oats, is a rich source of the soluble fibre β-glucan, which has been shown to significantly lower LDL-cholesterol (LDL-C). However, barley foods have been less widely studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOverweight; Hyperlipidemia
CountriesSouth Korea
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 26, 2011
Enrollment StartJun 1, 2010
Primary CompletionOct 1, 2010
Study CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 14.9 years ago

Interventions

Barley beta-glucan(3.0g)dietary

Barley beta-glucan(3.0g/day) for 12 weeks

Placebodietary

Placebo for 12 weeks